Understand what your menopause & HRT results really mean
See your biomarkers in context with a comprehensive panel.
- CLIA-certified labs
- HIPAA compliant
- Personalized health protocol
Menopause and the hormonal shift behind it
Menopause biomarkers are blood signals that track the winding down of ovarian function. They come from the ovaries and the brain’s hormone control center (pituitary) and reflect how many follicles remain and how actively they respond. Key markers include estrogen made by the ovaries (estradiol), pituitary messengers that stimulate the ovaries (follicle-stimulating hormone, FSH; luteinizing hormone, LH), ovarian growth signals that fade as egg supply declines (anti-Müllerian hormone, AMH), and ovarian feedback proteins (inhibin B). Together they map the feedback loop that steadies the menstrual cycle. As that loop loosens, levels shift in characteristic ways, revealing the transition from regular cycling to perimenopause and menopause. Testing helps distinguish menopausal change from other look-alike causes of symptoms, times conversations about contraception and symptom care, and anchors decisions about therapies. Because hormones fluctuate, patterns over time are often more telling than a single snapshot, turning biomarkers into a practical compass for where you are in the reproductive lifespan.
Why a hormone read sometimes helps the conversation
Menopause blood biomarkers map the shifting conversation between brain and ovaries that influences nearly every system—thermoregulation, sleep, mood, cognition, bone turnover, cardiovascular and metabolic health, and urogenital tissues. Measuring FSH, LH, estradiol, and progesterone makes that invisible transition visible. In cycling years, FSH and LH usually sit in the low-to-middle part of the lab range outside of ovulation, estradiol tends to fall in the mid-range across the follicular phase, and progesterone peaks toward the high end in the luteal phase. Through perimenopause, values swing widely. After menopause, FSH and LH are typically above the reproductive reference range, while estradiol and progesterone fall below it. During pregnancy, by contrast, FSH and LH are very low and estradiol and progesterone are high—helpful context when timing tests. When estradiol and progesterone drop, the hypothalamus loses its usual feedback and FSH/LH rise; low sex-steroid levels drive hot flashes, night sweats, irregular or absent periods, vaginal dryness and discomfort, reduced libido, sleep fragmentation, mood shifts, and brain “fog.” Lower estrogen accelerates bone resorption, raises LDL cholesterol, and can worsen insulin sensitivity, affecting long-term bone and heart health. If FSH and LH are unexpectedly low in the setting of menopausal symptoms, that pattern points away from ovarian aging and toward central (pituitary–hypothalamic) causes. Big picture: these hormones are the front door to a broader systems check. They connect ovarian aging to bone density, lipid profiles, vascular function, and cognitive and urogenital health, helping clarify stage (peri vs post) and informing surveillance for osteoporosis and cardiovascular risk over time.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
What hormone testing adds — and where clinical judgment leads
Menopause blood testing provides a window into the hormonal shifts that shape a woman’s health as she transitions out of her reproductive years. These changes affect not only fertility, but also energy levels, metabolism, cardiovascular risk, bone strength, cognitive function, and immune balance. At Superpower, we measure four key biomarkers—FSH (follicle-stimulating hormone), LH (luteinizing hormone), estradiol, and progesterone—to map this transition and its impact on the body’s interconnected systems. FSH and LH are hormones produced by the pituitary gland that regulate the menstrual cycle and ovulation. Estradiol and progesterone are ovarian hormones essential for reproductive function, but they also influence brain health, bone density, and cardiovascular stability. As menopause approaches, the ovaries gradually produce less estradiol and progesterone. In response, FSH and LH levels rise, signaling the body’s attempt to stimulate ovarian hormone production. Tracking these biomarkers helps clarify where someone is in the menopausal transition. Persistently high FSH and LH, alongside low estradiol and progesterone, indicate that the ovaries have reduced hormone output—a hallmark of menopause. This hormonal pattern reflects a new physiological balance, affecting everything from sleep and mood to bone and heart health. Interpretation of menopause blood tests depends on several factors, including age, menstrual history, pregnancy status, certain medications (like hormone therapy), and acute illness. Laboratory methods and reference ranges can also vary, so results are best understood in the context of the individual’s overall health and life stage.
Frequently Asked Questions
References
- Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ (2012). Executive summary of the Stages of Reproductive Aging Workshop + 10: Addressing the unfinished agenda of staging reproductive aging. *Menopause*, *19*(4), 387-395. https://doi.org/10.1097/gme.0b013e31824d8f40
- Burger H (2008). The menopausal transition--endocrinology. *The Journal of Sexual Medicine*, *5*(10), 2266-2273. https://doi.org/10.1111/j.1743-6109.2008.00921.x
- Su HI, Freeman EW (2009). Hormone changes associated with the menopausal transition. *Minerva Ginecologica*, *61*(6), 483-489. https://pubmed.ncbi.nlm.nih.gov/19942836/
- Matthews KA, Chen X, Barinas-Mitchell E, Brooks MM, Derby CA, Harlow S, Jackson EA, Thurston RC, El Khoudary SR (2021). Age at menopause in relationship to lipid changes and subclinical carotid disease across 20 years: Study of Women's Health Across the Nation. *Journal of the American Heart Association*, *10*(18), e021362. https://doi.org/10.1161/JAHA.121.021362
- Weitzmann MN, Pacifici R (2006). Estrogen deficiency and bone loss: An inflammatory tale. *The Journal of Clinical Investigation*, *116*(5), 1186-1194. https://doi.org/10.1172/JCI28550
